CI
RPRX icon

CX Institutional’s Royalty Pharma RPRX Stock Holding History

CX Institutional’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
346
+1
+0.3% +$52 ﹤0.01% 1187
2026
Q1 		$17K Buy
345
+293
+563% +$12.8K ﹤0.01% 1166
2025
Q4 		$2K Hold
52
– – ﹤0.01% 1394
2025
Q3 		$2K Hold
52
– – ﹤0.01% 1316
2025
Q2 		$2K Hold
52
– – ﹤0.01% 1158
2025
Q1 		$2K Buy
+52
New +$1.65K ﹤0.01% 1148

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CX Institutional's RPRX Position: Q2 2026 in Review

CX Institutional increased its Royalty Pharma (RPRX) stake by 0.29% in Q2 2026, buying an estimated $52 and bringing the position to 346 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1187.

CX Institutional first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • CX Institutional held 346 shares of Royalty Pharma worth $19K as of Q2 2026.
  • CX Institutional bought 1 Royalty Pharma share in Q2 2026, an estimated $52.
  • Royalty Pharma made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1187 holding.
  • CX Institutional first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.